Author: admin

The Cystic Fibrosis Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

“Cystic Fibrosis Pipeline Insight, 2024“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Cystic Fibrosis Market.

Some of the key takeaways from the Cystic Fibrosis Pipeline Report:

• Companies across the globe are diligently working toward developing novel Cystic Fibrosis treatment therapies with a considerable amount of success over the years. 

• Cystic Fibrosis companies working in the treatment market are Spirovant Sciences, Arcturus Therapeutics, Krystal Biotech, Vertex Pharmaceuticals, AbbVie, Armata Pharmaceuticals, 4D Molecular Therapeutics, Eloxx Pharmaceuticals, Verona Pharma, University of North Carolina, Aridis Pharmaceuticals, 4D Molecular Therapeutics, Boehringer Ingelheim, Hartford Hospital, Clarametyx Biosciences, Inc., Insmed Incorporated, Haisco Pharmaceutical, BiomX, Inc., Respirion Pharmaceuticals, and others, are developing therapies for the Cystic Fibrosis treatment 

• Emerging Cystic Fibrosis therapies in the different phases of clinical trials are- SP-101, LUNAR CF, KB407, Galicaftor/Navoc aftor/ABBV-576, AP-PA02, 4D-710, ELX-02, Ensifentrine, Deutivacaftor/tez acaftor/vanzacaft, Mannitol Inhalant Product, VX-522 mRNA therapy, Inhaled AR-501, 4D-710, BI 1291583, Cefiderocol, CMTX-101, Brensocatib, HSK31858, BX004-A, RSP-1502, and others are expected to have a significant impact on the Cystic Fibrosis market in the coming years.   

• In March 2024, Sionna Therapeutics has secured $182 million in a Series C financing round to further develop additional cystic fibrosis treatments for clinical trials. This round, which was increased and oversubscribed, will enable Sionna to continue advancing its clinical development of therapies aimed at stabilizing the first nucleotide-binding domain (NBD1) in cystic fibrosis patients.

• In August 2023, Porosome Therapeutics has announced a potentially innovative treatment for cystic fibrosis, revealing that it has filed a comprehensive patent for this new therapy targeting cystic fibrosis and other diseases. The biopharma describes this treatment as the first application of the porosome, the secretory portal in cells. Porosomes are lipoproteins located at the cell plasma membrane that facilitate cellular communication by secreting chemical messages essential for sustaining life. Defects in porosome secretion are linked to diseases such as neurological disorders, immune disorders, various cancers, diabetes, and cystic fibrosis.

Cystic Fibrosis Overview

Cystic fibrosis (CF) is a genetic disorder that primarily affects the respiratory and digestive systems. It is caused by mutations in the CFTR (cystic fibrosis transmembrane conductance regulator) gene, which encodes a protein responsible for regulating the movement of salt and water in and out of cells.

Get a Free Sample PDF Report to know more about Cystic Fibrosis Pipeline Therapeutic Assessment-

https://www.delveinsight.com/report-store/cystic-fibrosis-pipeline-insight

Emerging Cystic Fibrosis Drugs Under Different Phases of Clinical Development Include:

• SP-101: Spirovant Sciences

• LUNAR CF: Arcturus Therapeutics

• KB407: Krystal Biotech

• Galicaftor/Navoc aftor/ABBV-576: AbbVie

• AP-PA02: Armata Pharmaceuticals

• 4D-710: 4D Molecular Therapeutics

• ELX-02: Eloxx Pharmaceuticals

• Ensifentrine: Verona Pharma

• Deutivacaftor/tez acaftor/vanzacaft: Vertex Pharmaceuticals

• Mannitol Inhalant Product: University of North Carolina

• VX-522 mRNA therapy: Vertex Pharmaceuticals

• Inhaled AR-501: Aridis Pharmaceuticals

• 4D-710: 4D Molecular Therapeutics

• BI 1291583: Boehringer Ingelheim

• Cefiderocol: Hartford Hospital

• CMTX-101: Clarametyx Biosciences, Inc.

• Brensocatib: Insmed Incorporated

• HSK31858: Haisco Pharmaceutical

• BX004-A: BiomX, Inc.

• RSP-1502: Respirion Pharmaceuticals

Cystic Fibrosis Route of Administration

Cystic Fibrosis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as 

• Oral

• Parenteral

• Intravenous

• Subcutaneous

• Topical

Cystic Fibrosis Molecule Type

Cystic Fibrosis Products have been categorized under various Molecule types, such as

• Monoclonal Antibody

• Peptides

• Polymer

• Small molecule

• Gene therapy 

Cystic Fibrosis Pipeline Therapeutics Assessment

• Cystic Fibrosis Assessment by Product Type

• Cystic Fibrosis By Stage and Product Type

• Cystic Fibrosis Assessment by Route of Administration

• Cystic Fibrosis By Stage and Route of Administration

• Cystic Fibrosis Assessment by Molecule Type

• Cystic Fibrosis by Stage and Molecule Type

DelveInsight’s Cystic Fibrosis Report covers around 80+ products under different phases of clinical development like

• Late-stage products (Phase III)

• Mid-stage products (Phase II)

• Early-stage product (Phase I)

• Pre-clinical and Discovery stage candidates

• Discontinued & Inactive candidates

• Route of Administration

Further Cystic Fibrosis product details are provided in the report. Download the Cystic Fibrosis pipeline report to learn more about the emerging Cystic Fibrosis therapies

Some of the key companies in the Cystic Fibrosis Therapeutics Market include:

Key companies developing therapies for Cystic Fibrosis are – F. Hoffmann-La Roche Ltd, Gilead Sciences Inc., Mylan NV, AbbVie Inc., Alaxia, Allergan, AstraZeneca, Beyond Air Inc., Teva Pharmaceutical Industries Ltd, Vertex Pharmaceuticals Incorporated, and others.

Cystic Fibrosis Pipeline Analysis:

The Cystic Fibrosis pipeline report provides insights into 

• The report provides detailed insights about companies that are developing therapies for the treatment of Cystic Fibrosis with aggregate therapies developed by each company for the same.

• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Cystic Fibrosis Treatment.

• Cystic Fibrosis key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

• Cystic Fibrosis Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 

• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Cystic Fibrosis market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Cystic Fibrosis drugs and therapies

Cystic Fibrosis Pipeline Market Drivers

• Rising incidence of Cystic Fibrosis, advance research and development over the last few years have contributed to get a clearer picture of the disease, development of the healthcare industry are some of the important factors that are fueling the Cystic Fibrosis Market.

Cystic Fibrosis Pipeline Market Barriers

• However, No standard cure for cystic fibrosis, adverse effects associated with the drugs and other factors are creating obstacles in the Cystic Fibrosis Market growth.

Scope of Cystic Fibrosis Pipeline Drug Insight    

• Coverage: Global

• Key Cystic Fibrosis Companies: Spirovant Sciences, Arcturus Therapeutics, Krystal Biotech, Vertex Pharmaceuticals, AbbVie, Armata Pharmaceuticals, 4D Molecular Therapeutics, Eloxx Pharmaceuticals, Verona Pharma, University of North Carolina, Aridis Pharmaceuticals, 4D Molecular Therapeutics, Boehringer Ingelheim, Hartford Hospital, Clarametyx Biosciences, Inc., Insmed Incorporated, Haisco Pharmaceutical, BiomX, Inc., Respirion Pharmaceuticals, and others

• Key Cystic Fibrosis Therapies: SP-101, LUNAR CF, KB407, Galicaftor/Navoc aftor/ABBV-576, AP-PA02, 4D-710, ELX-02, Ensifentrine, Deutivacaftor/tez acaftor/vanzacaft, Mannitol Inhalant Product, VX-522 mRNA therapy, Inhaled AR-501, 4D-710, BI 1291583, Cefiderocol, CMTX-101, Brensocatib, HSK31858, BX004-A, RSP-1502, and others

• Cystic Fibrosis Therapeutic Assessment: Cystic Fibrosis current marketed and Cystic Fibrosis emerging therapies

• Cystic Fibrosis Market Dynamics: Cystic Fibrosis market drivers and Cystic Fibrosis market barriers 

Request for Sample PDF Report for Cystic Fibrosis Pipeline Assessment and clinical trials

Table of Contents

1. Cystic Fibrosis Report Introduction

2. Cystic Fibrosis Executive Summary

3. Cystic Fibrosis Overview

4. Cystic Fibrosis- Analytical Perspective In-depth Commercial Assessment

5. Cystic Fibrosis Pipeline Therapeutics

6. Cystic Fibrosis Late Stage Products (Phase II/III)

7. Cystic Fibrosis Mid Stage Products (Phase II)

8. Cystic Fibrosis Early Stage Products (Phase I)

9. Cystic Fibrosis Preclinical Stage Products

10. Cystic Fibrosis Therapeutics Assessment

11. Cystic Fibrosis Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. Cystic Fibrosis Key Companies

14. Cystic Fibrosis Key Products

15. Cystic Fibrosis Unmet Needs

16 . Cystic Fibrosis Market Drivers and Barriers

17. Cystic Fibrosis Future Perspectives and Conclusion

18. Cystic Fibrosis Analyst Views

19. Appendix

20. About DelveInsight

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +919650213330
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Cystic Fibrosis Pipeline Drugs Analysis Report, 2024: FDA Approvals, Clinical Trials, Therapies, MOA, ROA by DelveInsight | Krystal Biotech, Vertex Pharma, AbbVie, Armata Pharma, 4D Molecular Therapeu

The Follicular Lymphoma Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

“Follicular Lymphoma Pipeline Insight, 2024“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Follicular Lymphoma Market.

Some of the key takeaways from the Follicular Lymphoma Pipeline Report:

• Companies across the globe are diligently working toward developing novel Follicular Lymphoma treatment therapies with a considerable amount of success over the years. 

• Follicular Lymphoma companies working in the treatment market are InnoCare Pharma, Allogene Therapeutics, HUTCHMED, Sound Biologics, Xynomic Pharmaceuticals, ADC Therapeutics, AstraZeneca, Dr Reddy’s Laboratories, MAB WORKS, and others, are developing therapies for the Follicular Lymphoma treatment 

• Emerging Follicular Lymphoma therapies in the different phases of clinical trials are- ICP 248, ALLO-501, HMPL-689, PSB 202, Abexinostat, Loncastuximab tesirine, Acalabrutinib, DRL_RI, MIL62, and others are expected to have a significant impact on the Follicular Lymphoma market in the coming years.   

• In February 2024, The FDA has granted Priority Review to AbbVie and Genmab’s Epkinly (epcoritamab) for a supplemental biologics license application (sBLA) aimed at treating difficult-to-treat relapsed or refractory (r/r) follicular lymphoma (FL), a slow-growing type of lymphoma, after at least two prior lines of systemic therapy. Despite the emergence of new treatments and chimeric antigen receptor (CAR)-T cell therapy, there remains a substantial unmet need for managing r/r FL with effective and more convenient therapies, which Epkinly aims to address.

• IN November 2023, Bayer, a multinational pharmaceutical company based in Germany, has revealed intentions to voluntarily retract its new drug application in the United States for Aliqopa (copanlisib) in the treatment of relapsed follicular lymphoma (FL) due to an unsuccessful trial. This determination follows discussions between the company and the US Food and Drug Administration (FDA) regarding the trial data for Aliqopa’s efficacy.

Follicular Lymphoma Overview

Follicular lymphoma (FL) is a type of non-Hodgkin lymphoma (NHL), a cancer that originates in the lymphatic system, which is part of the body’s immune system. FL specifically arises from abnormal B-lymphocytes, a type of white blood cell, and typically grows slowly over time.

Get a Free Sample PDF Report to know more about Follicular Lymphoma Pipeline Therapeutic Assessment-

https://www.delveinsight.com/report-store/follicular-lymphoma-pipeline-insight

Emerging Follicular Lymphoma Drugs Under Different Phases of Clinical Development Include:

• ICP 248: InnoCare Pharma

• ALLO-501: Allogene Therapeutics

• HMPL-689: HUTCHMED

• PSB 202: Sound Biologics

• Abexinostat: Xynomic Pharmaceuticals

• Loncastuximab tesirine: ADC Therapeutics

• Acalabrutinib: AstraZeneca

• DRL_RI: Dr Reddy’s Laboratories

• MIL62: MAB WORKS

Follicular Lymphoma Route of Administration

Follicular Lymphoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as 

• Intra-articular

• Intraocular

• Intrathecal

• Intravenous

• Ophthalmic

• Oral

• Parenteral

• Subcutaneous

• Topical

• Transdermal

Follicular Lymphoma Molecule Type

Follicular Lymphoma Products have been categorized under various Molecule types, such as

• Oligonucleotide

• Peptide

• Small molecule

Follicular Lymphoma Pipeline Therapeutics Assessment

• Follicular Lymphoma Assessment by Product Type

• Follicular Lymphoma By Stage and Product Type

• Follicular Lymphoma Assessment by Route of Administration

• Follicular Lymphoma By Stage and Route of Administration

• Follicular Lymphoma Assessment by Molecule Type

• Follicular Lymphoma by Stage and Molecule Type

DelveInsight’s Follicular Lymphoma Report covers around 50+ products under different phases of clinical development like

• Late-stage products (Phase III)

• Mid-stage products (Phase II)

• Early-stage product (Phase I)

• Pre-clinical and Discovery stage candidates

• Discontinued & Inactive candidates

• Route of Administration

Further Follicular Lymphoma product details are provided in the report. Download the Follicular Lymphoma pipeline report to learn more about the emerging Follicular Lymphoma therapies

Some of the key companies in the Follicular Lymphoma Therapeutics Market include:

Key companies developing therapies for Follicular Lymphoma are – Epizyme, Eisai, Bayer Healthcare Pharmaceuticals, Verastem Oncology, Gilead Sciences, TG Therapeutics, ADC Therapeutics, Incyte Corporation, MorphoSys, AbbVie, Janssen Research & Development, Regeneron Pharmaceuticals, Novartis, MEI Pharma, BeiGene, Xynomic Pharmaceuticals, Bristol Myers Squibb, and others.

Follicular Lymphoma Pipeline Analysis:

The Follicular Lymphoma pipeline report provides insights into 

• The report provides detailed insights about companies that are developing therapies for the treatment of Follicular Lymphoma with aggregate therapies developed by each company for the same.

• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Follicular Lymphoma Treatment.

• Follicular Lymphoma key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

• Follicular Lymphoma Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 

• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Follicular Lymphoma market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Follicular Lymphoma drugs and therapies

Follicular Lymphoma Pipeline Market Drivers

• Increase in prevalence of Follicular Lymphoma, emergence of effective novel therapies, increased Research and Developmental Activities are some of the important factors that are fueling the Follicular Lymphoma Market.

Follicular Lymphoma Pipeline Market Barriers

• However, lack Of Cost-Effective Treatment, progression of disease within 2 years (POD24) in the Disease and other factors are creating obstacles in the Follicular Lymphoma Market growth.

Scope of Follicular Lymphoma Pipeline Drug Insight    

• Coverage: Global

• Key Follicular Lymphoma Companies: InnoCare Pharma, Allogene Therapeutics, HUTCHMED, Sound Biologics, Xynomic Pharmaceuticals, ADC Therapeutics, AstraZeneca, Dr Reddy’s Laboratories, MAB WORKS, and others

• Key Follicular Lymphoma Therapies: ICP 248, ALLO-501, HMPL-689, PSB 202, Abexinostat, Loncastuximab tesirine, Acalabrutinib, DRL_RI, MIL62, and others

• Follicular Lymphoma Therapeutic Assessment: Follicular Lymphoma current marketed and Follicular Lymphoma emerging therapies

• Follicular Lymphoma Market Dynamics: Follicular Lymphoma market drivers and Follicular Lymphoma market barriers 

Request for Sample PDF Report for Follicular Lymphoma Pipeline Assessment and clinical trials

Table of Contents

1. Follicular Lymphoma Report Introduction

2. Follicular Lymphoma Executive Summary

3. Follicular Lymphoma Overview

4. Follicular Lymphoma- Analytical Perspective In-depth Commercial Assessment

5. Follicular Lymphoma Pipeline Therapeutics

6. Follicular Lymphoma Late Stage Products (Phase II/III)

7. Follicular Lymphoma Mid Stage Products (Phase II)

8. Follicular Lymphoma Early Stage Products (Phase I)

9. Follicular Lymphoma Preclinical Stage Products

10. Follicular Lymphoma Therapeutics Assessment

11. Follicular Lymphoma Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. Follicular Lymphoma Key Companies

14. Follicular Lymphoma Key Products

15. Follicular Lymphoma Unmet Needs

16 . Follicular Lymphoma Market Drivers and Barriers

17. Follicular Lymphoma Future Perspectives and Conclusion

18. Follicular Lymphoma Analyst Views

19. Appendix

20. About DelveInsight

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Follicular Lymphoma Pipeline and Clinical Trials Assessment 2024: FDA Approvals, Therapies and Key Companies involved by DelveInsight | AstraZeneca, InnoCare Pharma, Allogene Therapeutics, HUTCHMED

The Neuroendocrine Tumors Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

“Neuroendocrine Tumors Pipeline Insight, 2024” report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Neuroendocrine Tumors Market.

Some of the key takeaways from the Neuroendocrine Tumors Pipeline Report: 

• Companies across the globe are diligently working toward developing novel Neuroendocrine Tumors treatment therapies with a considerable amount of success over the years. 

• Neuroendocrine Tumors companies working in the treatment market are Immunomic Therapeutics, Crinetics Pharmaceuticals, Biotheus, Panavance Therapeutics, Nano Pharmaceuticals, Oxford BioTherapeutics, Seneca Therapeutics, Amgen, POINT Biopharma, RayzeBio, and others, are developing therapies for the Neuroendocrine Tumors treatment 

• Emerging Neuroendocrine Tumors therapies in the different phases of clinical trials are- ITI 3000, Paltusotine, PM8002, GP-2250, BG-P-TAT, OBT-620, SVV-001, Tarlatamab, PNT2003, RYZ101, and others are expected to have a significant impact on the Neuroendocrine Tumors market in the coming years.   

• In May 2023, Amgen commenced a Phase III study involving tarlatamab versus standard of care for individuals experiencing relapsed small cell lung cancer after initial platinum-based chemotherapy. This trial is actively enrolling participants and is projected to conclude by June 2025, aiming for an estimated enrollment of 700 participants.

• In March 2023, RayzeBio, Inc., a company focused on targeted radiopharmaceuticals for solid tumors, reported the conclusion of enrollment for the Phase 1b segment within the ACTION-1 Phase 1b/3 trial evaluating RYZ101. This trial involves patients with SSTR+ gastroenteropancreatic neuroendocrine tumors (GEP-NETs) who experienced progression after receiving Lutetium-177 labeled somatostatin analog therapy.

• In March 2023, NUCLIDIUM revealed that the Neuroendocrine Tumors Research Foundation (“NETRF”) has chosen the company along with its collaborative partner, the University Hospital Basel (Universitätsspital Basel, “USB”), as recipients of its Investigator Award. This funding will aid in commencing and conducting a Phase 1 clinical trial featuring TraceNETTM, an innovative copper-based radiodiagnostic tool designed for detecting neuroendocrine tumors (NET).

Neuroendocrine Tumors Overview

Neuroendocrine tumors (NETs) are a diverse group of tumors that originate from neuroendocrine cells. These cells are found throughout the body, particularly in organs such as the gastrointestinal tract, pancreas, lungs, and adrenal glands. Neuroendocrine cells have characteristics of both nerve cells and hormone-producing cells, hence the name.

Get a Free Sample PDF Report to know more about Neuroendocrine Tumors Pipeline Therapeutic Assessment-

https://www.delveinsight.com/report-store/neuroendocrine-tumors-pipeline-insight

Emerging Neuroendocrine Tumors Drugs Under Different Phases of Clinical Development Include:

• ITI 3000: Immunomic Therapeutics

• Paltusotine: Crinetics Pharmaceuticals

• PM8002: Biotheus

• GP-2250: Panavance Therapeutics

• BG-P-TAT: Nano Pharmaceuticals

• OBT-620: Oxford BioTherapeutics

• SVV-001: Seneca Therapeutics

• Tarlatamab: Amgen

• PNT2003: POINT Biopharma

• RYZ101: RayzeBio

Neuroendocrine Tumors Route of Administration

Neuroendocrine Tumors pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as 

• Oral

• Parenteral

• Intravenous

• Subcutaneous

• Topical.

Neuroendocrine Tumors Molecule Type

Neuroendocrine Tumors Products have been categorized under various Molecule types, such as

• Monoclonal Antibody

• Peptides

• Polymer

• Small molecule

• Gene therapy

Neuroendocrine Tumors Pipeline Therapeutics Assessment

• Neuroendocrine Tumors Assessment by Product Type

• Neuroendocrine Tumors By Stage and Product Type

• Neuroendocrine Tumors Assessment by Route of Administration

• Neuroendocrine Tumors By Stage and Route of Administration

• Neuroendocrine Tumors Assessment by Molecule Type

• Neuroendocrine Tumors by Stage and Molecule Type

DelveInsight’s Neuroendocrine Tumors Report covers around 60+ products under different phases of clinical development like

• Late-stage products (Phase III)

• Mid-stage products (Phase II)

• Early-stage product (Phase I)

• Pre-clinical and Discovery stage candidates

• Discontinued & Inactive candidates

• Route of Administration

Further Neuroendocrine Tumors product details are provided in the report. Download the Neuroendocrine Tumors pipeline report to learn more about the emerging Neuroendocrine Tumors therapies

Some of the key companies in the Neuroendocrine Tumors Therapeutics Market include:

Key companies developing therapies for Neuroendocrine Tumors are – Pfizer, Takeda Oncology, Hutchison MediPharma, Provectus Biopharmaceuticals, NanoValent Pharmaceuticals, Camurus, ITM Solucin, Radiomedix, Inc., Orano Med LLC, Clarity Pharmaceuticals, TaiRx, Jiangsu Hengrui Medicine, MedImmune, Genentech, Merck & Co, Peloton Therapeutics, RayzeBio, Ascentage Pharma, Debiopharm, Boehringer Ingelheim, Roche, Ipsen, Medelis Inc., Exelixis, EpicentRx, Inc., Tarveda Therapeutics, Teclison Ltd., Novatek Pharmaceuticals, Phanes Therapeutics, Fujifilm Pharmaceuticals, Jazz Pharmaceuticals, 23andMe, Inc., Celgene, Crinetics Pharmaceuticals Inc., POINT Biopharma, and others.

Neuroendocrine Tumors Pipeline Analysis:

The Neuroendocrine Tumors pipeline report provides insights into 

• The report provides detailed insights about companies that are developing therapies for the treatment of Neuroendocrine Tumors with aggregate therapies developed by each company for the same.

• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Neuroendocrine Tumors Treatment.

• Neuroendocrine Tumors key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

• Neuroendocrine Tumors Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 

• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Neuroendocrine Tumors market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Neuroendocrine Tumors drugs and therapies

Neuroendocrine Tumors Pipeline Market Drivers

• Rising prevalence of the disease, growing Research and Development Activities are some of the important factors that are fueling the Neuroendocrine Tumors Market.

Neuroendocrine Tumors Pipeline Market Barriers

• However, limited Awareness and Under diagnosis, heterogeneity and Complexity and other factors are creating obstacles in the Neuroendocrine Tumors Market growth.

Scope of Neuroendocrine Tumors Pipeline Drug Insight    

• Coverage: Global

• Key Neuroendocrine Tumors Companies: Immunomic Therapeutics, Crinetics Pharmaceuticals, Biotheus, Panavance Therapeutics, Nano Pharmaceuticals, Oxford BioTherapeutics, Seneca Therapeutics, Amgen, POINT Biopharma, RayzeBio, and others

• Key Neuroendocrine Tumors Therapies: ITI 3000, Paltusotine, PM8002, GP-2250, BG-P-TAT, OBT-620, SVV-001, Tarlatamab, PNT2003, RYZ101, and others

• Neuroendocrine Tumors Therapeutic Assessment: Neuroendocrine Tumors current marketed and Neuroendocrine Tumors emerging therapies

• Neuroendocrine Tumors Market Dynamics: Neuroendocrine Tumors market drivers and Neuroendocrine Tumors market barriers 

Request for Sample PDF Report for Neuroendocrine Tumors Pipeline Assessment and clinical trials

Table of Contents

1. Neuroendocrine Tumors Report Introduction

2. Neuroendocrine Tumors Executive Summary

3. Neuroendocrine Tumors Overview

4. Neuroendocrine Tumors- Analytical Perspective In-depth Commercial Assessment

5. Neuroendocrine Tumors Pipeline Therapeutics

6. Neuroendocrine Tumors Late Stage Products (Phase II/III)

7. Neuroendocrine Tumors Mid Stage Products (Phase II)

8. Neuroendocrine Tumors Early Stage Products (Phase I)

9. Neuroendocrine Tumors Preclinical Stage Products

10. Neuroendocrine Tumors Therapeutics Assessment

11. Neuroendocrine Tumors Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. Neuroendocrine Tumors Key Companies

14. Neuroendocrine Tumors Key Products

15. Neuroendocrine Tumors Unmet Needs

16 . Neuroendocrine Tumors Market Drivers and Barriers

17. Neuroendocrine Tumors Future Perspectives and Conclusion

18. Neuroendocrine Tumors Analyst Views

19. Appendix

20. About DelveInsight

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Neuroendocrine Tumors Pipeline Assessment, 2024 Updates | In-depth Insights into Latest FDA, EMA, and PMDA Approvals, Clinical Trials, and Treatment Outlook | Pfizer, Takeda Oncology, Hutchison

The Rhinitis Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

“Rhinitis Pipeline Insight, 2024“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Rhinitis Market.

Some of the key takeaways from the Rhinitis Pipeline Report:

• Companies across the globe are diligently working toward developing novel Rhinitis treatment therapies with a considerable amount of success over the years. 

• Rhinitis companies working in the treatment market are Funpep, Inimmune, Chia Tai Tianqing Pharmaceutical Group, Iltoo Pharma, Revolo Biotherapeutics, Anhui Palo Alto Pharmaceuticals, Inmunotek SL, Abdi Ibrahim Pharmaceuticals, Regeneron, Revelation Biosciences, Qyuns Therapeutics, Hyloris Pharmaceuticals, and others, are developing therapies for the Rhinitis treatment 

• Emerging Rhinitis therapies in the different phases of clinical trials are- FPP004, INI 2004, TQC 3564, ILT-101, IRL201104, PA9159, MM09-MG01, AI201901, REGN1908-1909, Glycopyranosyl lipid adjuvant, QX 005N, HY-083, and others are expected to have a significant impact on the Rhinitis market in the coming years.   

• In June 2023, Longbio Pharma (Suzhou) has announced encouraging top-line findings from a Phase I clinical trial of LP-003, a novel long-acting anti-IgE antibody designed for allergic rhinitis treatment. This double-blind, randomized study assessed the pharmacokinetics, pharmacodynamics (free IgE levels), and safety of LP-003 in healthy participants.

• In May 2023, Altamira Therapeutics Ltd. (Nasdaq: CYTO), a company committed to addressing critical unmet medical needs, has disclosed favorable and statistically significant top-line outcomes from the randomized controlled NASAR clinical trial assessing its Bentrio nasal spray in individuals with seasonal allergic rhinitis (SAR). Bentrio nasal spray is crafted as a drug-free and preservative-free gel emulsion aimed at providing protection against airborne allergens like pollen or house dust mites. 

Rhinitis Overview

Rhinitis is a medical term used to describe inflammation of the mucous membrane lining the nose. It is a common condition that typically presents with symptoms such as a runny or congested nose, sneezing, itching, and nasal discharge. Rhinitis can be classified into several types, including allergic rhinitis, non-allergic rhinitis, and infectious rhinitis.

Get a Free Sample PDF Report to know more about Rhinitis Pipeline Therapeutic Assessment-

https://www.delveinsight.com/report-store/rhinitis-pipeline

Emerging Rhinitis Drugs Under Different Phases of Clinical Development Include:

• FPP004: Funpep

• INI 2004: Inimmune

• TQC 3564: Chia Tai Tianqing Pharmaceutical Group

• ILT-101: Iltoo Pharma

• IRL201104: Revolo Biotherapeutics

• PA9159: Anhui Palo Alto Pharmaceuticals

• MM09-MG01: Inmunotek SL

• AI201901: Abdi Ibrahim Pharmaceuticals

• REGN1908-1909: Regeneron

• Glycopyranosyl lipid adjuvant: Revelation Biosciences

• QX 005N: Qyuns Therapeutics

• HY-083: Hyloris Pharmaceuticals

Rhinitis Route of Administration

Rhinitis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as 

• Oral

• Parenteral

• Intravenous

• Subcutaneous

• Topical

Rhinitis Molecule Type

Rhinitis Products have been categorized under various Molecule types, such as

• Monoclonal Antibody

• Peptides

• Polymer

• Small molecule

• Gene therapy 

Rhinitis Pipeline Therapeutics Assessment

• Rhinitis Assessment by Product Type

• Rhinitis By Stage and Product Type

• Rhinitis Assessment by Route of Administration

• Rhinitis By Stage and Route of Administration

• Rhinitis Assessment by Molecule Type

• Rhinitis by Stage and Molecule Type

DelveInsight’s Rhinitis Report covers around 35+ products under different phases of clinical development like

• Late-stage products (Phase III)

• Mid-stage products (Phase II)

• Early-stage product (Phase I)

• Pre-clinical and Discovery stage candidates

• Discontinued & Inactive candidates

• Route of Administration

Further Rhinitis product details are provided in the report. Download the Rhinitis pipeline report to learn more about the emerging Rhinitis therapies

Some of the key companies in the Rhinitis Therapeutics Market include:

Key companies developing therapies for Rhinitis are – Regeneron, Revolo Biotherapeutics, Anhui Palo Alto Pharmaceuticals, Inc., Abdi Ibrahim Pharmaceuticals, Inmunotek, Iltoo Pharma, Advagene Biopharma Co. Ltd., AOBiome LLC, Emergo Therapeutics, Inimmune, Paradigm Biopharmaceuticals, Siolta Therapeutics, Revelation Biosciences Inc., Allergy Therapeutics, NeuCen BioMed, CSPC ZhongQi Pharmaceutical Technology Co., Ltd., Marinomed Biotech, Dobecure, Hyloris Pharmaceuticals, Qyuns Therapeutics, Worg Pharmaceuticals, Altamira Therapeutics, DC4U, Desentum, Funpep, and others.

Rhinitis Pipeline Analysis:

The Rhinitis pipeline report provides insights into 

• The report provides detailed insights about companies that are developing therapies for the treatment of Rhinitis with aggregate therapies developed by each company for the same.

• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Rhinitis Treatment.

• Rhinitis key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

• Rhinitis Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 

• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Rhinitis market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Rhinitis drugs and therapies

Rhinitis Pipeline Market Drivers

• Increase in the prevalence of various form of rhinitis, surge in the demand for effective and potent drugs among consumers across the globe are some of the important factors that are fueling the Rhinitis Market.

Rhinitis Pipeline Market Barriers

• However, high competition from generic drugs, side-effects associated with the rhinitis treatment and other factors are creating obstacles in the Rhinitis Market growth.

Scope of Rhinitis Pipeline Drug Insight    

• Coverage: Global

• Key Rhinitis Companies: Funpep, Inimmune, Chia Tai Tianqing Pharmaceutical Group, Iltoo Pharma, Revolo Biotherapeutics, Anhui Palo Alto Pharmaceuticals, Inmunotek SL, Abdi Ibrahim Pharmaceuticals, Regeneron, Revelation Biosciences, Qyuns Therapeutics, Hyloris Pharmaceuticals, and others

• Key Rhinitis Therapies: FPP004, INI 2004, TQC 3564, ILT-101, IRL201104, PA9159, MM09-MG01, AI201901, REGN1908-1909, Glycopyranosyl lipid adjuvant, QX 005N, HY-083, and others

• Rhinitis Therapeutic Assessment: Rhinitis current marketed and Rhinitis emerging therapies

• Rhinitis Market Dynamics: Rhinitis market drivers and Rhinitis market barriers 

Request for Sample PDF Report for Rhinitis Pipeline Assessment and clinical trials

Table of Contents 

1. Rhinitis Report Introduction

2. Rhinitis Executive Summary

3. Rhinitis Overview

4. Rhinitis- Analytical Perspective In-depth Commercial Assessment

5. Rhinitis Pipeline Therapeutics

6. Rhinitis Late Stage Products (Phase II/III)

7. Rhinitis Mid Stage Products (Phase II)

8. Rhinitis Early Stage Products (Phase I)

9. Rhinitis Preclinical Stage Products

10. Rhinitis Therapeutics Assessment

11. Rhinitis Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. Rhinitis Key Companies

14. Rhinitis Key Products

15. Rhinitis Unmet Needs

16 . Rhinitis Market Drivers and Barriers

17. Rhinitis Future Perspectives and Conclusion

18. Rhinitis Analyst Views

19. Appendix

20. About DelveInsight

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Rhinitis Pipeline and Clinical Trials Assessment 2024: FDA Approvals, Therapies and Key Companies involved by DelveInsight | Iltoo Pharma, Revolo Biotherapeutics, Anhui Palo Alto Pharma, Inmunotek SL